Results 231 to 240 of about 87,055 (290)

Entinostat plus exemestane for hormone receptor-positive advanced breast cancer: long-term overall survival results from the EOC103A3101 randomized controlled trial. [PDF]

open access: yesSignal Transduct Target Ther
Wang J   +17 more
europepmc   +1 more source

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combination

open access: yes
Arrighetti N   +19 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Inside HDAC With HDAC Inhibitors

European Journal of Medicinal Chemistry, 2010
Histone deacetylase inhibitors are a large group of diverse molecules intrinsically able to inhibit cell proliferation in various cancer cell lines. Their apoptotic effects have been linked to the modulation in the expression of several regulatory tumor suppressor genes caused by the modified status of histone acetylation, a key event in chromatin ...
Philippe Bertrand
exaly   +3 more sources

Selective Class II HDAC Inhibitors Impair Myogenesis by Modulating the Stability and Activity of HDAC–MEF2 Complexes [PDF]

open access: yesEMBO Reports, 2009
Histone deacetylase (HDAC) inhibitors are promising new epi-drugs, but the presence of both class I and class II enzymes in HDAC complexes precludes a detailed elucidation of the individual HDAC functions.
Angela Nebbioso   +2 more
exaly   +3 more sources

NO-HDAC Dual Inhibitors

European Journal of Medicinal Chemistry, 2022
HDAC inhibitors and NO donors have both demonstrated independently broad therapeutic potential in a variety of diseases. Borretto et al. presented the topic of NO-HDAC dual inhibitors for the first time in 2013 as an attractive new topic. Here we collected the general structure of all synthesized NO-HDAC dual inhibitors, lead compounds, synthesis ...
Razieh Ghodsi, Negar Omidkhah
exaly   +3 more sources

Home - About - Disclaimer - Privacy